Use of contraindicated antiplatelet medications in the setting of percutaneous coronary intervention

Geoffrey D. Barnes, Maggie A. Stanislawski, Wenhui Liu, Anna E. Barón, Ehrin J. Armstrong, P. Michael Ho, Andrew Klein, Thomas M. Maddox, Brahmajee K. Nallamothu, John S. Rumsfeld, Thomas T. Tsai, Steven M. Bradley

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Background - Several antiplatelet medications used during and after percutaneous coronary intervention (PCI) are contraindicated for specific patient groups. A broad assessment of contraindicated medication use and associated clinical outcomes is not well described. Methods and Results - Using national Veterans Affairs Clinical Assessment, Reporting, and Tracking Program data for all PCI between 2007 and 2013, we evaluated patients with contraindications to commonly used antiplatelet medications during and after PCI, defined in accordance with package inserts. Adjusted association between contraindicated medication use and outcomes of periprocedural bleeding and 30-day mortality were assessed using Cox proportional hazards with inverse probability weighting. Among 64 294 patients undergoing PCI, 11 315(17.6%) had a contraindication to a common antiplatelet medication and 737 (6.5%) of these patients received a contraindicated medication. In unadjusted analyses, any contraindicated medication use was associated with both increased bleeding and 30-day mortality. In adjusted models, contraindicated abciximab use in patients with thrombocytopenia (hazard ratio, 2.23; 95% confidence interval, 1.58-3.16) and in patients with a previous stroke (hazard ratio, 1.93; 95% confidence interval, 1.37-2.71) remained significantly associated with increased bleeding. Contraindicated abciximab use was not significantly associated with 30-day mortality in adjusted models. Use of eptifibatide in dialysis patients was not significantly associated with an increased risk of bleeding or mortality. Conclusions - In this national cohort, ≈18% of patients undergoing PCI had contraindications to common antiplatelet medications. Approximately 6% of those patients received a contraindicated medication with attendant bleeding risk, although this did not translate into significantly higher risk of 30-day mortality. Continued efforts to reduce contraindicated medication use may help avoid periprocedural complications.

Original languageEnglish
Pages (from-to)406-413
Number of pages8
JournalCirculation: Cardiovascular Quality and Outcomes
Volume9
Issue number4
DOIs
StatePublished - Jul 1 2016
Externally publishedYes

Keywords

  • abciximab
  • eptifibatide
  • medication errors
  • mortality
  • percutaneous coronary intervention

Fingerprint Dive into the research topics of 'Use of contraindicated antiplatelet medications in the setting of percutaneous coronary intervention'. Together they form a unique fingerprint.

  • Cite this

    Barnes, G. D., Stanislawski, M. A., Liu, W., Barón, A. E., Armstrong, E. J., Ho, P. M., Klein, A., Maddox, T. M., Nallamothu, B. K., Rumsfeld, J. S., Tsai, T. T., & Bradley, S. M. (2016). Use of contraindicated antiplatelet medications in the setting of percutaneous coronary intervention. Circulation: Cardiovascular Quality and Outcomes, 9(4), 406-413. https://doi.org/10.1161/CIRCOUTCOMES.115.002043